Immature Dental Pulp Stem Cell Isolation Under Hypoxic Culture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for obtaining large numbers of pluripotent and homogeneous dental pulp stem cells (DPSCs) are inefficient, leading to senescence and genetic abnormalities, limiting their therapeutic potential due to age-related regenerative decline and challenges in large-scale production.
Innovation Solution
A non-enzymatic method of isolating multifunctional immature dental pulp stem cells (IDPSCs) is developed, maintaining their undifferentiated state through prolonged culturing of dental pulp explants under hypoxic conditions, ensuring minimal loss of stemness and reduced tumorigenicity, with multilineage orientation proven by in vitro and in vivo markers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional methods are used to obtain large numbers of pluripotent DPSCs, then the quantity of stem cells increases, but the cells undergo senescence and develop genetic abnormalities
Solution Approach 1:
The patent changes critical culture parameters including switching to non-enzymatic treatment, adjusting passage number limits (harvesting at passage 3-5), modifying culture medium composition, and controlling hypoxic conditions. These parameter changes enable large-scale production while preventing senescence and genetic abnormalities, resolving the contradiction between quantity and quality.
Solution Approach 2:
The patent performs preliminary characterization and selection of DPSCs at early passages (3-5) before senescence and genetic abnormalities occur. By harvesting cells at this predetermined early stage and maintaining them in a defined state, the method ensures high cell quality while achieving sufficient quantity for therapeutic applications.
2Stability of the object's composition
If prolonged culturing is performed to maintain stemness, then the undifferentiated state is preserved, but the production time increases
Solution Approach 1:
The patent performs preliminary expansion of DPSCs to passage 3-5 where cells maintain stemness, then harvests and cryopreserves them. This preliminary action allows banks of authenticated stem cells to be prepared in advance, reducing future production time while maintaining stability through controlled early-passage culture.
Solution Approach 2:
The patent establishes continuous non-enzymatic culture conditions with optimized media and hypoxic atmosphere that sustain stemness through multiple passages. This continuous optimized action enables long-term maintenance of stem cells without differentiation, balancing time investment with stability preservation.
3Productivity
If enzymatic treatment is used to isolate stem cells, then the isolation efficiency improves, but the cell population becomes heterogeneous and less homogeneous
Solution Approach 1:
The patent inverts the conventional approach by using non-enzymatic treatment instead of enzymatic digestion to isolate DPSCs. This inversion preserves cell homogeneity and prevents damage to cell surfaces and extracellular matrix, while still achieving efficient isolation through mechanical and physical methods.
Solution Approach 2:
The patent replaces enzymatic treatment with non-enzymatic mechanical and physical methods for cell isolation. This substitution eliminates the harmful effects of enzymes on cell homogeneity and structure, while maintaining isolation efficiency through alternative mechanical separation techniques.
4Quantity of substance
If large-scale production is implemented to meet clinical needs, then the quantity of cells increases, but the risk of tumorigenicity increases
Solution Approach 1:
The patent performs preliminary characterization, karyotyping, and stemness assessment at early passages (3-5) before expansion to large scale. By authentication and banking cells at this early stage with controlled genetics, the method prevents tumorigenicity while enabling large-scale production from authenticated cell banks.
Solution Approach 2:
The patent changes critical parameters including limiting passage number (harvesting at passage 3-5), optimizing culture conditions to prevent genetic instability, and using non-enzymatic treatment to preserve cell integrity. These parameter changes decouple large-scale production from increased tumorigenicity risk by maintaining genetic stability throughout expansion.
Data Source
AI summary
The present invention is directed to therapeutic multifunctional immature dental pulp stem cells (IDPSCs), and IDPSCs multi-lineage compositions. The invention is further directed to the use of IDPSCs and compositions to reduce the risk of and/or treat degenerative diseases or for other medicinal and aesthetic purposes.